Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

[1]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[2]  I. Hirsch,et al.  The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies , 2017, Current medical research and opinion.

[3]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[4]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[5]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[6]  K. Ranade,et al.  Reductions in eosinophil biomarkers by benralizumab in patients with asthma. , 2016, Respiratory Medicine.

[7]  David Price,et al.  Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice , 2016, Journal of asthma and allergy.

[8]  A. Klion,et al.  Biologic therapies targeting eosinophils: current status and future prospects. , 2015, The journal of allergy and clinical immunology. In practice.

[9]  P. Paggiaro,et al.  Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study , 2015, BMJ Open.

[10]  Pr Depo-Provera.  PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION , 2015 .

[11]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[12]  James J. Lee,et al.  The consequences of not having eosinophils , 2013, Allergy.

[13]  W. Busse,et al.  The poorly explored impact of uncontrolled asthma. , 2013, Chest.

[14]  Teresa To,et al.  Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.

[15]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[16]  S. Wenzel,et al.  Tissue and BAL based biomarkers in asthma. , 2007, Immunology and allergy clinics of North America.